# Synthetic Cannabinoids Schedule I Placement: April 2026 Updates > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement-april-2026/ > **Published:** 2026-04-12T14:14:24-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T14:01:48-04:00 > **Clinical Summary:** Review the latest synthetic cannabinoids Schedule I placement and DEA regulatory updates relevant to cannabis clinicians in April 2026. --- Policy WatchApril 12, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal Register [Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) Regulatory Summary The DEA placed 3-methoxyphencyclidine (a synthetic drug analog) in Schedule I, establishing it as a controlled substance with no medical use—relevant to cannabis clinicians as a precedent for synthetic substance scheduling and drug classification policy. [Read more →](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Regulatory Summary The DEA temporarily placed bromazolam (a benzodiazepine analog) in Schedule I, which may impact cannabis clinicians’ ability to recommend complementary anxiolytic medications for patients seeking cannabis alternatives. [Read more →](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act](https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) Regulatory Summary This DEA action schedules benzodiazepine analogs as Schedule I controlled substances, relevant to cannabis clinicians managing anxiety or seizures who may consider alternative or complementary treatment approaches. [Read more →](https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://www.federalregister.gov/documents/2026/01/20/2026-00954/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i) Regulatory Summary The DEA temporarily placed 2-fluorodeschloroketamine, a ketamine analog, in Schedule I, which may affect cannabis clinicians using ketamine-assisted therapy protocols alongside cannabis treatment. [Read more →](https://www.federalregister.gov/documents/2026/01/20/2026-00954/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i) This regulatory action schedules 4-fluoroamphetamine as a controlled substance, which is minimally relevant to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) as it addresses synthetic amphetamine analogs rather than cannabis therapeutics or clinical practice. [Read more →](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I](https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino) This regulatory action schedules two synthetic opioids as controlled substances, with limited direct relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) unless cannabis is used clinically to address opioid-related conditions or manage pain in patients. [Read more →](https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino) Score 70Federal Register [Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl) This regulation schedules synthetic opioids under DEA control; it does not directly affect cannabis medicine but reflects broader controlled substance policy that may influence prescribing practices for cannabis clinicians treating pain patients. [Read more →](https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl) Score 70Federal Register [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and) Regulatory Summary The DEA placed four synthetic cannabinoids into Schedule I, restricting their legal availability and establishing criminal penalties for possession, directly affecting cannabis clinicians’ understanding of prohibited alternatives and patients’ legal treatment options. [Read more →](https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Regulatory Summary This action temporarily schedules bromazolam (a benzodiazepine analog) as a Schedule I controlled substance, relevant to cannabis clinicians who may encounter drug interactions or co-prescription considerations with cannabis-using patients. [Read more →](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i) The DEA placed CUMYL-PEGACLONE, a synthetic cannabinoid, into Schedule I, restricting its legal use and reinforcing the regulatory framework distinguishing illicit synthetic cannabinoids from regulated cannabis medicine. [Read more →](https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i) Digest-Level Clinical Commentary Dr. Caplan’s Take Clinical Reflection These regulatory actions targeting novel synthetic drugs rather than cannabis itself suggest that the controlled substances landscape is evolving in ways that have limited direct implications for established cannabis medicine practice, since none of these items involve cannabis or cannabinoids. What this digest does signal is the DEA’s ongoing focus on designer drug proliferation in the illicit market, which indirectly affects my patient population by reinforcing distinctions between regulated [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) and uncontrolled synthetic alternatives that patients might otherwise consider. For cannabis medicine practitioners, this regulatory activity underscores the importance of educating patients that evidence-based [cannabinoid therapeutics](https://cedclinic.com/medcan3-trial-cancer-symptoms/) operate within a fundamentally different legal and safety framework than the synthetic compounds being scheduled. Clinical Perspective Clinical Perspective These scheduling actions reflect an ongoing regulatory response to the proliferation of novel synthetic drugs that circumvent existing controlled substance laws through minor chemical modifications. The substances listed represent several drug classes with significant abuse potential and clinical consequences, including synthetic cathinones, benzodiazepine analogues, dissociatives, opioid analogues, and synthetic cannabinoids, many of which have emerged in illicit markets with little safety or efficacy data. Healthcare providers should remain aware that these compounds may present with atypical toxidromes or complicate toxicological screening, requiring heightened clinical suspicion when evaluating patients with substance use or intoxication presentations, particularly as these novel agents continue to evolve ahead of regulatory classification. Drug PolicyControlled Substances[DEA Regulations](https://cedclinic.com/nitazene-synthetic-opioids-temporary-schedule-i-placement/)Synthetic Drugs 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+April+12%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+April+12%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Mystery ‘Fake Pot’ Liquid Seized In Washington Tagged As New JWH-018-S, Feds Say](https://cedclinic.com/synthetic-cannabinoids-patient-safety-regulation/) - [Exploring Cannabinoids and Their Role in Patient Care – Cannabis News | NUG Magazine](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) - [High Marijuana Taxes Don’t Effectively Deter Use, Study Shows, Contrary To NYT Editorial …](https://cedclinic.com/cannabis-tax-increases-patient-use-study-insights/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Policy Watch: 10 Regulatory Updates — April 01, 2026](https://cedclinic.com/dea-scheduling-benzodiazepines-2026-regulatory-updates/) Explore the regulatory landscape with the April 1, 2026 update covering controlled substances and synthetic [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/). [Read April 1 Updates](https://cedclinic.com/dea-scheduling-benzodiazepines-2026-regulatory-updates/) [Policy Watch: 20 Regulatory Updates — April 25, 2026](https://cedclinic.com/schedules-controlled-substances-placement-april-2026/) Stay informed on the latest regulatory changes impacting synthetic cannabinoids and controlled substances in late April 2026. [Read April 25 Updates](https://cedclinic.com/schedules-controlled-substances-placement-april-2026/) [Policy Watch: 27 Regulatory Updates — March 16, 2026](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/) Review a comprehensive summary of regulatory updates including synthetic [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/) from March 2026. [Read March 16 Updates](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).